Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia.
Quy LeSommer CastroThao TangAnisha M LoebTiffany HylkemaCyd Nourigat McKayLaKeisha PerkinsShivani SrivastavaLindsey CallJenny SmithAmanda LeontiRhonda E RiesLaura PardoMichael R LokenColin CorrentiSalvatore FiorenzaCameron J TurtleStanley RiddellKatherine TarlockSoheil MeshinchiPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
These findings demonstrate that MSLN is a viable target for CAR T-cell therapy in AML and that inhibiting MSLN shedding is a promising approach to improve CAR T-cell efficacy.